251 CONSUMERS ROAD, TORONTO, A6
Aptose Biosciences Inc. Shareholders Approve Continuance Resolution
Leading Independent Proxy Advisory Firm Endorses Plan of Arrangement
Aptose Biosciences Inc. Amends Employment Agreement with Dr. William Rice
Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” Proposed Plan of Arrangement
Ex-99.1
Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition Pending Final Clearance from SEC
Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose Biosciences Enters Definitive Arrangement Agreement with Hanmi
FY 2025
Q3
Q2
Q1
FY 2024
RW
Schedule 13E-3 - Going Private Transaction
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Definitive Merger Proxy Statement
PRER14A
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Schedule 13E-3 - Going Private Transaction
PREM14A
Submission Upload